{"id":14016,"date":"2025-11-05T21:40:53","date_gmt":"2025-11-05T13:40:53","guid":{"rendered":"https:\/\/zoomax.com\/?p=14016"},"modified":"2026-05-18T17:10:24","modified_gmt":"2026-05-18T09:10:24","slug":"breakthroughs-in-age-related-macular-degeneration-treatment-bridging-new-therapies-with-low-vision-solutions","status":"publish","type":"post","link":"https:\/\/zoomax.com\/ar\/breakthroughs-in-age-related-macular-degeneration-treatment-bridging-new-therapies-with-low-vision-solutions\/","title":{"rendered":"\u0627\u062e\u062a\u0631\u0627\u0642\u0627\u062a \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a \u0627\u0644\u0645\u0631\u062a\u0628\u0637 \u0628\u0627\u0644\u0639\u0645\u0631: \u0627\u0644\u0631\u0628\u0637 \u0628\u064a\u0646 \u0627\u0644\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u062c\u062f\u064a\u062f\u0629 \u0648\u062d\u0644\u0648\u0644 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Age-related macular degeneration (AMD) stands as a leading cause of irreversible vision loss worldwide, affecting over 200 million people globally\u2014and that number is projected to rise as populations age. For decades, AMD patients, particularly those with the dry form that accounts for 85-90% of cases, faced a bleak prognosis: gradual central vision loss leading to low vision or even legal blindness, with limited treatment options to halt or reverse the damage. \u00a0However, 2025 has marked a transformative year in AMD care, with breakthroughs in dry macular degeneration treatment and innovations in AMD disease treatment, emerging alongside advanced \u0645\u0639\u064a\u0646\u0627\u062a \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631<\/a> for macular degeneration like \u0632\u0648\u0645\u0627\u0643\u0633<\/a> LUNA 6, SNOW 12, and LUNA EYE. These devices are bridging the gap between medical progress and daily functionality.<\/p>

\u0641\u0647\u0645 \u0645\u0631\u0636 AMD \u0648\u0623\u0632\u0645\u0629 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631<\/h2>

\u0644\u0641\u0647\u0645 \u062a\u0623\u062b\u064a\u0631 \u0627\u0644\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u062c\u062f\u064a\u062f\u0629\u060c \u0645\u0646 \u0627\u0644\u0636\u0631\u0648\u0631\u064a \u0623\u0648\u0644\u0627\u064b \u0625\u062f\u0631\u0627\u0643 \u0627\u0644\u0635\u0644\u0629 \u0628\u064a\u0646 AMD \u0648\u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631. \u064a\u064f\u0639\u0631\u0651\u0641 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0628\u0623\u0646\u0647 \u0636\u0639\u0641 \u0628\u0635\u0631 \u062f\u0627\u0626\u0645 \u0644\u0627 \u064a\u0645\u0643\u0646 \u062a\u0635\u062d\u064a\u062d\u0647 \u0628\u0627\u0644\u0646\u0638\u0627\u0631\u0627\u062a \u0623\u0648 \u0627\u0644\u0639\u062f\u0633\u0627\u062a \u0627\u0644\u0644\u0627\u0635\u0642\u0629 \u0623\u0648 \u0627\u0644\u062c\u0631\u0627\u062d\u0629 \u0623\u0648 \u0627\u0644\u0623\u062f\u0648\u064a\u0629\u060c \u0648\u0644\u0643\u0646\u0647 \u064a\u062a\u0631\u0643 \u0628\u0639\u0636 \u0627\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0645\u062a\u0628\u0642\u064a\u0629 \u0627\u0644\u062a\u064a \u064a\u0645\u0643\u0646 \u062a\u062d\u0633\u064a\u0646\u0647\u0627 \u0628\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0623\u062f\u0648\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0639\u062f\u0629. \u0628\u0627\u0644\u0646\u0633\u0628\u0629 \u0644\u0645\u0631\u0636\u0649 AMD\u060c \u064a\u0638\u0647\u0631 \u0630\u0644\u0643 \u0639\u0644\u0649 \u0634\u0643\u0644 \u0641\u0642\u062f\u0627\u0646 \u062a\u062f\u0631\u064a\u062c\u064a \u0644\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0645\u0631\u0643\u0632\u064a\u0629 - \u201c\u0628\u0642\u0639 \u0636\u0628\u0627\u0628\u064a\u0629 \u0623\u0648 \u0645\u0634\u0648\u0647\u0629\u201d \u0641\u064a \u0648\u0633\u0637 \u0645\u062c\u0627\u0644 \u0627\u0644\u0631\u0624\u064a\u0629 - \u0628\u064a\u0646\u0645\u0627 \u062a\u0638\u0644 \u0627\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0645\u062d\u064a\u0637\u064a\u0629 \u0633\u0644\u064a\u0645\u0629 \u0641\u064a \u0643\u062b\u064a\u0631 \u0645\u0646 \u0627\u0644\u0623\u062d\u064a\u0627\u0646. \u0648\u0627\u0644\u0646\u062a\u064a\u062c\u0629 \u0647\u064a \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0642\u062f\u0631\u0629 \u0639\u0644\u0649 \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0623\u0648 \u0627\u0644\u062a\u0639\u0631\u0641 \u0639\u0644\u0649 \u0627\u0644\u0648\u062c\u0648\u0647 \u0623\u0648 \u0627\u0644\u0642\u064a\u0627\u062f\u0629 \u0623\u0648 \u0623\u062f\u0627\u0621 \u0627\u0644\u0645\u0647\u0627\u0645 \u0627\u0644\u064a\u0648\u0645\u064a\u0629 \u0645\u062b\u0644 \u0627\u0644\u0637\u0647\u064a \u0623\u0648 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u0634\u0624\u0648\u0646 \u0627\u0644\u0645\u0627\u0644\u064a\u0629 - \u0648\u0647\u064a \u0623\u0646\u0634\u0637\u0629 \u064a\u0639\u062a\u0628\u0631\u0647\u0627 \u0645\u0639\u0638\u0645 \u0627\u0644\u0646\u0627\u0633 \u0623\u0645\u0631\u0627\u064b \u0645\u0641\u0631\u0648\u063a\u0627\u064b \u0645\u0646\u0647.<\/p>

\"wet<\/p>

Dry AMD, the more common subtype, involves the slow degeneration of retinal photoreceptor cells in the macula, the part of the eye responsible for sharp central vision. Until recently, treatments focused on slowing progression rather than restoring function, leaving millions reliant on macular degeneration low vision aids to navigate life. Wet AMD, though less prevalent, progresses faster due to abnormal blood vessel growth under the retina, but has seen more treatment options with wet macular degeneration treatment breakthroughs using anti-VEGF medications.<\/p>

\u062a\u0645\u062a\u062f \u0627\u0644\u0623\u0632\u0645\u0629 \u0625\u0644\u0649 \u0645\u0627 \u0647\u0648 \u0623\u0628\u0639\u062f \u0645\u0646 \u0627\u0644\u0642\u064a\u0648\u062f \u0627\u0644\u062c\u0633\u062f\u064a\u0629: \u064a\u0631\u062a\u0628\u0637 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0646\u0627\u062c\u0645 \u0639\u0646 \u0645\u0631\u0636 AMD \u0628\u0632\u064a\u0627\u062f\u0629 \u0645\u0639\u062f\u0644\u0627\u062a \u0627\u0644\u0627\u0643\u062a\u0626\u0627\u0628 \u0648\u0627\u0644\u0639\u0632\u0644\u0629 \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639\u064a\u0629 \u0648\u0641\u0642\u062f\u0627\u0646 \u062c\u0648\u062f\u0629 \u0627\u0644\u062d\u064a\u0627\u0629. \u0647\u0630\u0627 \u0647\u0648 \u0627\u0644\u0633\u0628\u0628 \u0641\u064a \u0623\u0646 \u0627\u0644\u062a\u0642\u0627\u0631\u0628 \u0628\u064a\u0646 \u0627\u0644\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u062c\u062f\u064a\u062f\u0629 \u0644\u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0646\u0627\u062a\u062c \u0639\u0646 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 AMD \u0648\u0627\u0644\u0645\u0633\u0627\u0639\u062f\u0627\u062a \u0627\u0644\u0625\u0644\u0643\u062a\u0631\u0648\u0646\u064a\u0629 \u0627\u0644\u0645\u062a\u0642\u062f\u0645\u0629 \u0644\u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u064a\u0639\u062f \u062b\u0648\u0631\u0629 \u0643\u0628\u064a\u0631\u0629 - \u0641\u0647\u0648 \u064a\u0639\u0627\u0644\u062c \u0627\u0644\u0633\u0628\u0628 \u0627\u0644\u062c\u0630\u0631\u064a \u0644\u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0648\u0627\u0644\u0627\u062d\u062a\u064a\u0627\u062c\u0627\u062a \u0627\u0644\u0648\u0638\u064a\u0641\u064a\u0629 \u0627\u0644\u0641\u0648\u0631\u064a\u0629 \u0644\u0644\u0645\u0631\u0636\u0649\u060c \u0645\u0645\u0627 \u064a\u062e\u0644\u0642 \u0646\u0647\u062c\u064b\u0627 \u0623\u0643\u062b\u0631 \u0634\u0645\u0648\u0644\u064a\u0629 \u0644\u0644\u0631\u0639\u0627\u064a\u0629. \u0628\u0627\u0644\u0646\u0633\u0628\u0629 \u0644\u0623\u0648\u0644\u0626\u0643 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0628\u0627\u0644\u0641\u0639\u0644 \u0645\u0646 \u062a\u062f\u0647\u0648\u0631 \u0627\u0644\u0628\u0635\u0631\u060c \u0641\u0625\u0646 \u0641\u0647\u0645 \u0643\u064a\u0641\u064a\u0629 \u0627\u0644\u0645\u0627\u0646\u0627<\/em>\u064a\u0635\u0628\u062d \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a \u0627\u0644\u0646\u0627\u062c\u0645 \u0639\u0646 \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a \u062c\u0632\u0621\u064b\u0627 \u0645\u0647\u0645\u064b\u0627 \u0645\u0646 \u0631\u062d\u0644\u062a\u0647\u0645\u060c \u062d\u064a\u062b \u064a\u0645\u0632\u062c \u0628\u064a\u0646 \u0627\u0644\u062a\u062f\u062e\u0644 \u0627\u0644\u0637\u0628\u064a \u0648\u0627\u0644\u0623\u062f\u0648\u0627\u062a \u0627\u0644\u0639\u0645\u0644\u064a\u0629 \u0627\u0644\u062a\u064a \u062a\u062d\u0648\u0644 \u0627\u0644\u062a\u062d\u062f\u064a\u0627\u062a \u0627\u0644\u064a\u0648\u0645\u064a\u0629 \u0625\u0644\u0649 \u0645\u0647\u0627\u0645 \u064a\u0645\u0643\u0646 \u0627\u0644\u062a\u062d\u0643\u0645 \u0641\u064a\u0647\u0627.<\/p>

\u062a\u0642\u0646\u064a\u0627\u062a \u0639\u0644\u0627\u062c AMD \u0627\u0644\u062a\u064a \u0633\u062a\u063a\u064a\u0631 \u0642\u0648\u0627\u0639\u062f \u0627\u0644\u0644\u0639\u0628\u0629 \u0641\u064a \u0639\u0627\u0645 2025<\/h2>

After years of research, 2025 has witnessed multiple macular degeneration treatment breakthroughs, moving from \u201cmanaging decline\u201d to \u201crestoring function.\u201d These macular degeneration new treatment 2025 technologies target different stages of AMD, offering hope for both early and advanced cases.<\/p>

\u063a\u0631\u0633\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 PRIMA: \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0631\u0624\u064a\u0629 \u0644\u0645\u0631\u0636 AMD \u0627\u0644\u062c\u0627\u0641 \u0627\u0644\u0645\u062a\u0642\u062f\u0645<\/h3>

\u0641\u064a \u0623\u0643\u062a\u0648\u0628\u0631 2025\u060c \u0643\u0634\u0641\u062a \u062f\u0631\u0627\u0633\u0629 \u0646\u064f\u0634\u0631\u062a \u0641\u064a \u0645\u062c\u0644\u0629 The New England Journal of Medicine \u0639\u0646 \u0646\u0638\u0627\u0645 PRIMA (\u0645\u0635\u0641\u0648\u0641\u0629 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u062f\u0642\u064a\u0642\u0629 \u0644\u0632\u0631\u0627\u0639\u0629 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0636\u0648\u0626\u064a\u0629)\u060c \u0648\u0647\u0648 \u0625\u0646\u062c\u0627\u0632 \u062c\u062f\u064a\u062f \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0645\u0631\u0636 AMD \u0627\u0644\u062c\u0627\u0641 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0648\u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a. \u0648\u064a\u062a\u0643\u0648\u0646 \u0627\u0644\u0646\u0638\u0627\u0645 \u0645\u0646 \u063a\u0631\u0633\u0629 \u0644\u0627\u0633\u0644\u0643\u064a\u0629 \u0635\u063a\u064a\u0631\u0629 \u0628\u062d\u062c\u0645 2 \u0645\u0645 \u00d7 2 \u0645\u0645 \u062a\u0648\u0636\u0639 \u062a\u062d\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0645\u0642\u062a\u0631\u0646\u0629 \u0628\u0646\u0638\u0627\u0631\u0627\u062a \u0645\u062a\u062e\u0635\u0635\u0629 \u0648\u0645\u0639\u0627\u0644\u062c \u0645\u062d\u0645\u0648\u0644. \u0639\u0644\u0649 \u0639\u0643\u0633 \u0627\u0644\u063a\u0631\u0633\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u062a\u0642\u0644\u064a\u062f\u064a\u0629\u060c \u064a\u0639\u0645\u0644 \u0646\u0638\u0627\u0645 PRIMA \u0628\u0627\u0644\u0636\u0648\u0621\u060c \u0645\u0645\u0627 \u064a\u0644\u063a\u064a \u0627\u0644\u062d\u0627\u062c\u0629 \u0625\u0644\u0649 \u0627\u0644\u0628\u0637\u0627\u0631\u064a\u0627\u062a \u0623\u0648 \u0627\u0644\u062a\u0648\u0635\u064a\u0644\u0627\u062a \u0627\u0644\u0633\u0644\u0643\u064a\u0629.<\/p>

\"primaIn a clinical trial of 38 patients, 81% experienced clinically significant vision improvement after 12 months\u2014equivalent to reading two more lines on a standard eye chart. Most patients regained the ability to read words, recognize faces, and perform daily tasks they had abandoned due to low vision. While 81% of participants reported temporary severe adverse events (mostly within the first two months post-surgery), 95% of these resolved quickly, and the implant did not harm peripheral vision. The PRIMA retinal implant success rate underscores its potential as a viable option for those with end-stage dry AMD, making it one of the most notable new treatments for dry macular degeneration 2025<\/strong>.<\/p>

\u064a\u0645\u062b\u0644 \u0646\u0638\u0627\u0645 PRIMA \u0646\u0642\u0644\u0629 \u0646\u0648\u0639\u064a\u0629 \u0628\u0627\u0644\u0646\u0633\u0628\u0629 \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0646\u062a\u0642\u0644\u0648\u0646 \u0645\u0646 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0625\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u062c\u0632\u0626\u064a. \u0648\u0645\u0639 \u0630\u0644\u0643\u060c \u064a\u062a\u0637\u0644\u0628 \u0627\u0644\u0646\u0638\u0627\u0645 \u0634\u0647\u0648\u0631\u064b\u0627 \u0645\u0646 \u0627\u0644\u062a\u062f\u0631\u064a\u0628 \u0644\u0625\u062a\u0642\u0627\u0646\u0647\u060c \u0648\u062e\u0644\u0627\u0644 \u0641\u062a\u0631\u0629 \u0627\u0644\u062a\u0643\u064a\u0641 \u0647\u0630\u0647, macular degeneration low vision aids<\/strong> like \u0632\u0648\u0645\u0627\u0643\u0633 \u0644\u0648\u0646\u0627 6<\/a> \u0644\u0644\u0645\u0647\u0627\u0645 \u0627\u0644\u062a\u064a \u062a\u062a\u0637\u0644\u0628 \u0631\u0624\u064a\u0629 \u062f\u0642\u064a\u0642\u0629 \u0639\u0646 \u0642\u0631\u0628\u060c \u0645\u062b\u0644 \u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u0637\u0628\u0648\u0639\u0627\u062a \u0627\u0644\u0635\u063a\u064a\u0631\u0629 \u0623\u0648 \u0645\u0644\u0621 \u0627\u0644\u0646\u0645\u0627\u0630\u062c\u060c \u0628\u064a\u0646\u0645\u0627 \u064a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u0632\u0631\u0639\u0629 \u0644\u0644\u0645\u0647\u0627\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0629 \u0627\u0644\u0623\u0648\u0633\u0639 \u0646\u0637\u0627\u0642\u0627\u064b.<\/p>

\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062d\u0631\u0627\u0631\u064a \u0627\u0644\u0641\u0646\u0644\u0646\u062f\u064a: \u062e\u064a\u0627\u0631 \u0637\u0641\u064a\u0641 \u0627\u0644\u062a\u0648\u063a\u0644 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 AMD \u0627\u0644\u062c\u0627\u0641 \u0627\u0644\u0645\u0628\u0643\u0631<\/h3>

\u0641\u064a \u0646\u0648\u0641\u0645\u0628\u0631 2025\u060c \u0623\u0639\u0644\u0646 \u0628\u0627\u062d\u062b\u0648\u0646 \u0641\u0646\u0644\u0646\u062f\u064a\u0648\u0646 \u0641\u064a \u062c\u0627\u0645\u0639\u0629 \u0622\u0644\u062a\u0648 \u0639\u0646 \u0639\u0644\u0627\u062c \u062d\u0631\u0627\u0631\u064a \u062c\u062f\u064a\u062f \u0644\u0645\u0631\u0636 AMD \u0627\u0644\u062c\u0627\u0641 \u0641\u064a \u0645\u0631\u0627\u062d\u0644\u0647 \u0627\u0644\u0645\u0628\u0643\u0631\u0629\u060c \u062d\u064a\u062b \u064a\u0642\u062f\u0645 \u0628\u062f\u064a\u0644\u0627\u064b \u063a\u064a\u0631 \u062c\u0631\u0627\u062d\u064a \u0644\u0625\u0628\u0637\u0627\u0621 \u0623\u0648 \u0639\u0643\u0633 \u062a\u0644\u0641 \u0627\u0644\u062e\u0644\u0627\u064a\u0627. \u0648\u064a\u0633\u062a\u062e\u062f\u0645 \u0627\u0644\u0639\u0644\u0627\u062c \u0636\u0648\u0621 \u0627\u0644\u0623\u0634\u0639\u0629 \u062a\u062d\u062a \u0627\u0644\u062d\u0645\u0631\u0627\u0621 \u0627\u0644\u0642\u0631\u064a\u0628\u0629 \u0645\u0646 \u0627\u0644\u0623\u0634\u0639\u0629 \u062a\u062d\u062a \u0627\u0644\u062d\u0645\u0631\u0627\u0621 \u0644\u062a\u0633\u062e\u064a\u0646 \u0623\u0646\u0633\u062c\u0629 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0628\u0644\u0637\u0641\u060c \u0645\u0645\u0627 \u064a\u0624\u062f\u064a \u0625\u0644\u0649 \u062a\u0646\u0634\u064a\u0637 \u0628\u0631\u0648\u062a\u064a\u0646\u0627\u062a \u0627\u0644\u0635\u062f\u0645\u0629 \u0627\u0644\u062d\u0631\u0627\u0631\u064a\u0629 \u0648\u0627\u0644\u0627\u0644\u062a\u0647\u0627\u0645 \u0627\u0644\u0630\u0627\u062a\u064a \u0627\u0644\u062e\u0644\u0648\u064a - \u0648\u0647\u064a \u0639\u0645\u0644\u064a\u0629 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0637\u0628\u064a\u0639\u064a\u0629 \u0644\u0625\u0635\u0644\u0627\u062d \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062a\u0627\u0644\u0641\u0629. \u0648\u062e\u0644\u0627\u0641\u0627\u064b \u0644\u0644\u0639\u0645\u0644\u064a\u0627\u062a \u0627\u0644\u062c\u0631\u0627\u062d\u064a\u0629 \u0627\u0644\u062c\u0631\u0627\u062d\u064a\u0629\u060c \u0641\u0625\u0646 \u0647\u0630\u0627 \u0627\u0644\u0639\u0644\u0627\u062c \u0644\u0627 \u064a\u0644\u0627\u0645\u0633 \u0627\u0644\u0628\u0634\u0631\u0629 \u0648\u063a\u064a\u0631 \u0645\u0624\u0644\u0645 \u0648\u064a\u0633\u062a\u0647\u062f\u0641 \u0641\u0642\u0637 \u0627\u0644\u0645\u0646\u0627\u0637\u0642 \u0627\u0644\u0645\u062a\u0636\u0631\u0631\u0629\u060c \u0645\u0645\u0627 \u064a\u062d\u0627\u0641\u0638 \u0639\u0644\u0649 \u0623\u0646\u0633\u062c\u0629 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0633\u0644\u064a\u0645\u0629.<\/p>

\"finnish<\/p>

Validated in animal models, the thermal therapy has shown promise in halting photoreceptor cell loss and even restoring some function. Clinical trials in humans are set to launch in spring 2026, with expectations of FDA approval within three years. This dry macular degeneration treatment breakthrough<\/strong> offers a minimally invasive option, reducing the risk of low vision progression for those in the early stages. For patients already experiencing mild low vision, combining thermal therapy with devices like<\/p>

\u0632\u0648\u0645\u0627\u0643\u0633 \u0633\u0646\u0648 12<\/a>- \u0648\u0647\u0648 \u0645\u0643\u0628\u0651\u0631 \u0625\u0644\u0643\u062a\u0631\u0648\u0646\u064a \u0645\u062a\u0637\u0648\u0631 \u0645\u0642\u0627\u0633 12 \u0628\u0648\u0635\u0629 \u0645\u0632\u0648\u062f \u0628\u0645\u064a\u0632\u0627\u062a \u0633\u0647\u0644\u0629 \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0645\u062e\u0635\u0635\u0629 - \u064a\u0645\u0643\u0646 \u0623\u0646 \u064a\u0633\u0627\u0639\u062f \u0641\u064a \u0627\u0644\u062d\u0641\u0627\u0638 \u0639\u0644\u0649 \u062c\u0648\u062f\u0629 \u0627\u0644\u062d\u064a\u0627\u0629 \u0623\u062b\u0646\u0627\u0621 \u0633\u0631\u064a\u0627\u0646 \u0627\u0644\u0639\u0644\u0627\u062c.<\/p>

\u0639\u0645\u0644\u064a\u0627\u062a \u0632\u0631\u0627\u0639\u0629 \u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0639\u064a\u0646 \u0628\u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062c\u0630\u0639\u064a\u0629: \u062a\u062c\u062f\u064a\u062f \u0627\u0644\u0623\u0646\u0633\u062c\u0629 \u0627\u0644\u0633\u0644\u064a\u0645\u0629<\/h3>

\u0641\u064a \u0633\u0628\u062a\u0645\u0628\u0631 2025\u060c \u0623\u062c\u0631\u0649 \u0627\u0644\u062c\u0631\u0627\u062d\u0648\u0646 \u0627\u0644\u064a\u0627\u0628\u0627\u0646\u064a\u0648\u0646 \u0641\u064a \u0643\u0648\u0628\u064a \u0623\u0648\u0644 \u0639\u0645\u0644\u064a\u0629 \u0632\u0631\u0627\u0639\u0629 \u0634\u0628\u0643\u064a\u0629 \u0646\u0627\u062c\u062d\u0629 \u0641\u064a \u0627\u0644\u0639\u0627\u0644\u0645 \u0628\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062c\u0630\u0639\u064a\u0629 \u0627\u0644\u0645\u0633\u062a\u062d\u062b\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0642\u062f\u0631\u0627\u062a (IPS)\u060c \u0648\u0647\u0648 \u0645\u0627 \u064a\u0639\u062f \u0625\u0646\u062c\u0627\u0632\u0627\u064b \u0647\u0627\u0645\u0627\u064b \u0644\u0645\u0631\u0636\u0649 AMD \u0641\u064a \u0645\u0631\u0627\u062d\u0644\u0647 \u0627\u0644\u0645\u062a\u0623\u062e\u0631\u0629. \u062a\u062a\u0645 \u0625\u0639\u0627\u062f\u0629 \u0628\u0631\u0645\u062c\u0629 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062c\u0630\u0639\u064a\u0629 \u0627\u0644\u0645\u0633\u062a\u062d\u062b\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0642\u062f\u0631\u0627\u062a - \u0627\u0644\u0645\u0633\u062a\u0645\u062f\u0629 \u0645\u0646 \u062c\u0644\u062f \u0627\u0644\u0645\u0631\u064a\u0636 \u0623\u0648 \u062f\u0645\u0647 - \u0644\u062a\u062a\u0637\u0648\u0631 \u0625\u0644\u0649 \u062e\u0644\u0627\u064a\u0627 \u0638\u0647\u0627\u0631\u064a\u0629 \u0635\u0628\u063a\u064a\u0629 \u0633\u0644\u064a\u0645\u0629 \u0644\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u062b\u0645 \u062a\u064f\u0632\u0631\u0639 \u0641\u064a \u0627\u0644\u0639\u064a\u0646 \u0644\u062a\u062d\u0644 \u0645\u062d\u0644 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062a\u0627\u0644\u0641\u0629 \u0641\u064a \u0627\u0644\u0628\u0642\u0639\u0629.<\/p>

\"ipsThe first patient, a woman with advanced AMD, experienced stable vision improvement within months of the surgery, regaining the ability to navigate independently and read with minimal assistance. This macular degeneration treatment breakthrough offers a regenerative approach, addressing the root cause of vision loss rather than just managing symptoms. For patients who have lived with severe low vision for years, IPS cell therapy could reduce dependence on macular degeneration aids, though many may still use \u0632\u0648\u0645\u0627\u0643\u0633 \u0644\u0648\u0646\u0627 \u0622\u064a \u0632\u0648\u0645\u0627\u0643\u0633<\/a>-\u0645\u0643\u0628\u0651\u0631 \u0641\u064a\u062f\u064a\u0648 \u0645\u0643\u062a\u0628\u064a \u0645\u0639 \u0623\u0648\u0636\u0627\u0639 \u0639\u0631\u0636 \u0645\u0631\u0646\u0629 - \u0644\u0644\u0645\u0647\u0627\u0645 \u0627\u0644\u062a\u064a \u062a\u062a\u0637\u0644\u0628 \u0631\u0624\u064a\u0629 \u0642\u0631\u064a\u0628\u0629 \u0645\u0633\u062a\u0645\u0631\u0629\u060c \u0645\u062b\u0644 \u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0643\u062a\u0628 \u0623\u0648 \u0627\u0644\u0639\u0645\u0644 \u0639\u0644\u0649 \u0627\u0644\u0643\u0645\u0628\u064a\u0648\u062a\u0631.<\/p>

\u0627\u0644\u062c\u0631\u0627\u062d\u0629 \u0627\u0644\u0631\u0648\u0628\u0648\u062a\u064a\u0629 \u0627\u0644\u062a\u064a \u062a\u0639\u0645\u0644 \u0628\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u062c\u064a\u0644 \u0627\u0644\u062e\u0627\u0645\u0633: \u0627\u0644\u062f\u0642\u0629 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 AMD \u0627\u0644\u0631\u0637\u0628 \u0648\u0627\u0644\u0646\u0632\u064a\u0641 \u0627\u0644\u0628\u0642\u0639\u064a<\/h3>

While dry AMD has dominated recent breakthroughs, wet AMD and related conditions like macular hemorrhage have seen their own wet macular degeneration treatment breakthroughs<\/strong>. In November 2025, a team from Sun Yat-sen University\u2019s Zhongshan Ophthalmic Center performed the world\u2019s first remote robotic subretinal injection using a domestically developed 5G ophthalmic robot. This procedure is critical for treating wet AMD, macular edema, and macular hemorrhage\u2014conditions that can cause rapid low vision if not treated promptly.<\/p>

\"5g<\/p>

The robot\u2019s 5G connection ensures zero latency, allowing surgeons to perform precise injections from miles away, expanding access to specialized care for patients in rural or underserved areas. For patients recovering from robotic surgery, macular degeneration medical devices like The Zoomax SNOW 12, with its high-contrast display and compatibility with distance-viewing camera \u0639\u064a\u0646 \u0627\u0644\u062b\u0644\u062c<\/a>, \u064a\u0633\u0627\u0639\u062f \u0627\u0644\u0645\u0631\u0636\u0649 \u0639\u0644\u0649 \u0627\u0644\u062a\u0643\u064a\u0641 \u0645\u0639 \u062a\u062d\u0633\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0645\u0639 \u062a\u0642\u0644\u064a\u0644 \u0625\u062c\u0647\u0627\u062f \u0627\u0644\u0639\u064a\u0646 \u0623\u062b\u0646\u0627\u0621 \u0627\u0644\u062a\u0639\u0627\u0641\u064a.<\/p>

\u0627\u0644\u062f\u0648\u0631 \u0627\u0644\u0630\u064a \u0644\u0627 \u063a\u0646\u0649 \u0639\u0646\u0647 \u0644\u0648\u0633\u0627\u0626\u0644 \u0627\u0644\u0645\u0633\u0627\u0639\u062f\u0629 \u0639\u0644\u0649 \u0627\u0644\u0625\u0628\u0635\u0627\u0631 \u0641\u064a \u0627\u0644\u0639\u0646\u0627\u064a\u0629 \u0628\u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631<\/h2>

While new therapies offer unprecedented hope, macular degeneration low vision aids and electronic magnifiers remain essential components of AMD care\u2014for three key reasons:<\/p>